<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Palmoplantar pustulosis: Treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Palmoplantar pustulosis: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Palmoplantar pustulosis: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Giovanna Brunasso, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cesare Massone, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristina Callis Duffin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H257468162"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Palmoplantar pustulosis (PPP) is an uncommon chronic skin disorder characterized by recurrent eruptions of pustules on the palms and soles  (<a class="graphic graphic_picture graphicRef75404 graphicRef62582 graphicRef82843 graphicRef93903 graphicRef93904 graphicRef93905" href="/z/d/graphic/75404.html" rel="external">picture 1A-F</a>). Scale, erythema, pruritus, burning sensations, and pain are common associated features.</p><p>Although PPP involves a limited area, the disorder can have a significant negative effect on quality of life and can interfere with performance of activities of daily living. Patients with PPP on the soles of the feet may experience difficulty walking, and hand involvement may interfere with other activities.</p><p>PPP tends to have a prolonged course consisting of periods of exacerbation and partial remission. The treatment of the disease is often challenging, as responses to individual treatments are variable and unpredictable.</p><p>The management of PPP will be reviewed here. The clinical manifestations and diagnosis of PPP are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/89272.html" rel="external">"Palmoplantar pustulosis: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H257463081"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>High-quality data on the treatment of palmoplantar pustulosis (PPP) are limited, contributing to uncertainty about the ideal approach to treatment. Although multiple randomized trials have been performed, most are small and of poor methodologic quality [<a href="#rid1">1</a>]. Moreover, the lack of a standardized method for assessing the response to treatment, as well as the wide variability in treatment regimens, complicate comparisons of study findings.</p><p>Because of the variable and unpredictable response to treatment, our therapeutic approach consists of first treating with generally well-tolerated therapies that have been reported to be effective for improving PPP in conjunction with benign general measures to minimize symptoms. Our preferred first-line therapies are topical corticosteroids, oral retinoids, and photochemotherapy. Patients who do not respond to these interventions are candidates for other treatments. (See <a class="local">'First-line therapy'</a> below and <a class="local">'Second-line therapy'</a> below.)</p><p class="headingAnchor" id="H257463087"><span class="h1">GENERAL MEASURES</span><span class="headingEndMark"> — </span>Regardless of the severity of the disease, we encourage all patients to engage in the following behavioral changes in an attempt to minimize symptoms and disease exacerbations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin moisturization </strong>–<strong> </strong>Moisturization of the skin can help to mediate the discomfort associated with palmoplantar pustulosis (PPP) by helping to minimize formation of cracks and fissures in skin. We encourage patients to apply a bland, unscented, emollient moisturizer on affected areas and surrounding skin several times daily as needed. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of irritants </strong>–<strong> </strong>Clinical experience suggests that skin irritation may contribute to exacerbations of PPP. In particular, we encourage patients to avoid wet work with the hands (eg, washing items with detergents or soaps) or to use gloves when engaging in such activity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking cessation </strong>–<strong> </strong>Although data are insufficient for definitive conclusions on the effect of smoking cessation on the course of PPP [<a href="#rid1">1</a>], we encourage all of our patients with PPP to stop smoking based upon knowledge of the strong link between smoking and PPP [<a href="#rid2">2</a>]. The findings of an uncontrolled prospective study of 63 adult smokers with PPP suggest there may be a benefit of smoking cessation; statistically significant improvements in the number of pustules and patient scores for disease severity were noted after three to six months among patients who stopped smoking, but not among the remainder of the patients [<a href="#rid3">3</a>]. A high dropout rate was among the limitations of this study. Additional studies are needed to explore the effect of smoking cessation. (See  <a class="medical medical_review" href="/z/d/html/89272.html" rel="external">"Palmoplantar pustulosis: Epidemiology, clinical features, and diagnosis", section on 'Pathogenesis'</a>.)</p><p></p><p class="headingAnchor" id="H257463093"><span class="h1">FIRST-LINE THERAPY</span><span class="headingEndMark"> — </span>First-line therapeutic options for palmoplantar pustulosis (PPP) include topical corticosteroids, an oral retinoid, and photochemotherapy. </p><p>Topical corticosteroids are often our initial choice for limited PPP (focal involvement on the palms or soles) based upon the ease of administration and well-tolerated nature of these agents. However, when patients present with extensive disease (diffuse palmar or plantar involvement) we usually begin oral retinoid treatment or photochemotherapy immediately in conjunction with topical corticosteroid therapy. </p><p class="headingAnchor" id="H257463099"><span class="h2">Topical corticosteroids</span><span class="headingEndMark"> — </span>Topical corticosteroid therapy is an accepted first-line therapy for PPP and is the most widely used treatment [<a href="#rid4">4,5</a>]. The major advantage of topical corticosteroid therapy is that it is a skin-directed treatment with a low risk for serious adverse effects that can be administered by the patient. Clinical follow-up to ensure proper use of topical corticosteroids is still required:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– There are few data on the efficacy of topical corticosteroids for PPP. An open-label right-left trial in which 19 patients with bilateral PPP were randomly assigned to apply <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> 0.1% cream (a medium potency topical corticosteroid) under a hydrocolloid dressing to sites of PPP on one side of the body every three days and to apply <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> propionate 0.05% cream (a super high-potency topical corticosteroid) twice daily without occlusion to the contralateral side found that both treatments induced improvement in PPP after four weeks [<a href="#rid6">6</a>]. However, significantly greater clinical improvement developed in sites treated with triamcinolone under occlusion than in sites treated with clobetasol without occlusion. Additionally, complete clearance occurred more frequently in the triamcinolone under occlusion areas (63 versus 16 percent of treated areas). Responses to both treatments were transient; symptoms recurred within a few weeks after treatment cessation. </p><p></p><p class="bulletIndent1">Benefit of topical corticosteroid therapy is also suggested by a retrospective study [<a href="#rid4">4</a>]. Among 49 patients with PPP who were treated with high potency topical corticosteroids (twice daily for up to four weeks followed by less frequent use of lower potency topical corticosteroids), marked, moderate, partial, and no improvement were documented in 27, 29, 20, and 24 percent of patients, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– Our preferred regimen for topical corticosteroid therapy is a super high-potency topical corticosteroid applied under occlusion  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 1</a>). We typically instruct patients to apply the topical corticosteroid under a hydrocolloid dressing. The topical corticosteroid and a hydrocolloid dressing are reapplied every three days until clearance of active PPP or for a maximum of four weeks. A response to treatment is usually evident within the first two weeks [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent1">If there are <strong>no</strong> signs of clinical improvement after four weeks or worsening of symptoms occurs, we usually begin oral retinoid treatment or photochemotherapy. If the patient has partial improvement that seems likely to continue to improve with a longer course of topical corticosteroid therapy, we continue topical corticosteroid monotherapy for up to an additional four weeks, but decrease the intensity of treatment as tolerated (eg, treatment in place two days per week). If the response remains insufficient, we transition to other treatments. (See <a class="local">'Oral retinoids'</a> below and <a class="local">'Photochemotherapy'</a> below.)</p><p></p><p class="bulletIndent1">Alternative methods to perform occlusion (eg, plastic wrap) are an option, but may require more frequent dressing changes. When plastic wrap occlusion is used, we instruct patients to apply the plastic wrap over the topical corticosteroid every night for one week, then every other night for two weeks followed by twice-weekly applications under plastic wrap for up to 13 additional weeks. Topical corticosteroids are not applied on the intervening occlusion-free days. We often see partial improvement within the first 10 to 20 days. </p><p></p><p class="bulletIndent1">Once patients achieve resolution of active disease with topical corticosteroid therapy, we institute maintenance therapy. Our goal is to reduce the intensity of treatment to application of the high potency topical corticosteroid <strong>without</strong> occlusion two days per week. </p><p></p><p class="bulletIndent1">Cutaneous atrophy is a potential adverse effect of topical corticosteroid therapy, particularly when high potency topical corticosteroids are used. The potential adverse effects of topical corticosteroid treatment are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H257463105"><span class="h2">Oral retinoids</span><span class="headingEndMark"> — </span>Systemic treatment with oral retinoids (eg, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, etretinate) can be effective for PPP:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– A 2006 systematic review identified several randomized trials that evaluated oral retinoid therapy for PPP [<a href="#rid1">1</a>]. Pooling of data from four randomized trials that compared etretinate with placebo demonstrated that 72 percent of 67 patients treated with etretinate compared with 28 percent of 60 patients given placebo showed some improvement in PPP (rate ratio 2.54, 95% CI 1.65-3.91). Moreover, 39 versus 17 percent, respectively, achieved good or excellent responses (rate ratio 2.31, 95% CI 1.20-4.46). The doses used for etretinate therapy in these trials varied; the duration of treatment ranged from 8 to 16 weeks. </p><p></p><p class="bulletIndent1">Although etretinate is no longer available in many locations, including the United States, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, a metabolite of etretinate, appears to be similarly effective for PPP. A randomized trial that compared etretinate with acitretin in 60 adults with PPP found that both treatments were similarly effective for improving clinical manifestations of PPP [<a href="#rid7">7</a>]. Patients in both groups were given 30 mg of the assigned medicine for four weeks followed by upward or downward dose adjustments according to clinical improvement and tolerance of therapy.</p><p></p><p class="bulletIndent1">Although <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a>, a newer oral retinoid, appeared beneficial for PPP in an uncontrolled study [<a href="#rid8">8</a>], a phase 2 randomized trial, in which 33 adults with PPP (with or without psoriasis) were randomly assigned in a 2:1 ratio to alitretinoin (30 mg once daily) or placebo for up to 24 weeks, did not find alitretinoin more effective than placebo [<a href="#rid9">9</a>]. Additional study is necessary to confirm the effects of alitretinoin in PPP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– Our preferred treatment regimen for PPP in adults is an initial three-month course of <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> (50 mg per day). We usually begin with a 25 mg dose of acitretin and increase the dose by 10 mg per week as tolerated. Reductions in dose to reduce side effects are sometimes necessary. </p><p></p><p class="bulletIndent1">Once satisfactory improvement is achieved, we aim to taper the drug to the lowest dose required to maintain improvement. In two randomized trials, maintenance treatment with etretinate demonstrated greater efficacy for maintaining remissions than placebo [<a href="#rid10">10,11</a>]. </p><p></p><p class="bulletIndent1">Side effects of oral retinoids can be limiting factors for therapy. Potential adverse effects include xerosis, cheilitis, dry mucous membranes, hypertriglyceridemia, hair loss, liver function test abnormalities, bone changes, and visual changes. Oral retinoids are teratogenic, and pregnancy should be avoided for three years following <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> therapy. Therefore, acitretin has a relative contraindication for use in women of childbearing age.</p><p></p><p class="headingAnchor" id="H257463111"><span class="h2">Photochemotherapy</span><span class="headingEndMark"> — </span>Psoralen plus ultraviolet A (PUVA) photochemotherapy, which involves the oral or topical administration of a psoralen (<a class="drug drug_general" data-topicid="9577" href="/z/d/drug information/9577.html" rel="external">methoxsalen</a>) prior to exposure of affected areas to ultraviolet A light, can be effective for PPP. We typically administer oral PUVA rather than topical PUVA because there is greater support for the efficacy of oral PUVA therapy. Also, in our experience, topical PUVA can be irritating to the skin and is poorly tolerated by some patients (see  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– The use of oral PUVA for PPP is supported by randomized trials that compared oral PUVA with placebo [<a href="#rid12">12,13</a>]. In a trial of 22 patients with bilateral PPP, a total of 30 treatment sessions of PUVA given four times per week on one randomly selected side of the body resulted in complete clearance of treated areas in 12 patients and great improvement in an additional five patients, whereas none of the untreated sides achieved these levels of improvement [<a href="#rid12">12</a>]. The difference in effect between treated and untreated areas was statistically significant. In most cases, improvement was not seen until 10 to 20 treatments were administered and the mean number of treatments required for clearance of lesions was 26 (range 18 to 30). </p><p></p><p class="bulletIndent1">The second trial compared oral PUVA (three times per week), etretinate (0.6 mg/kg per day), combination therapy with oral PUVA and etretinate, and placebo and no PUVA over a course of 12 weeks [<a href="#rid13">13</a>]. In this open trial, thirty patients with severe bilateral PPP were randomly assigned to etretinate or placebo therapy, and after two weeks began oral PUVA photochemotherapy on affected areas of one side of the body. The proportion of the 12 areas that received 12 weeks of PUVA monotherapy that cleared or exhibited much improvement was significantly greater than among the 12 affected areas assigned to placebo and no PUVA (75 versus 17 percent). The results among areas treated with etretinate monotherapy did not differ significantly from oral PUVA monotherapy, a finding that contrasts with another 12-week trial that favored etretinate over oral PUVA [<a href="#rid14">14</a>]. Combination therapy with an oral retinoid and PUVA appeared to be the most effective therapy. (See <a class="local">'Re-PUVA'</a> below.)</p><p></p><p class="bulletIndent1">Although favorable responses to topical PUVA have been documented [<a href="#rid12">12</a>], randomized trials evaluating topical PUVA have not demonstrated superior efficacy over placebo [<a href="#rid15">15,16</a>]. One trial comparing oral PUVA and topical PUVA did not find a significant difference in efficacy [<a href="#rid14">14</a>]. However, the response rates to oral PUVA reported in this trial were lower than reported in other studies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– We usually aim to administer oral PUVA three times per week and continue treatment for at least 12 weeks prior to concluding treatment inefficacy. Potential adverse effects of PUVA include burns, blistering, nausea, pruritus, phototoxicity, hyperpigmentation, premature aging of skin, and skin cancer. Adverse effects of PUVA are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H257463117"><span class="h1">SECOND-LINE THERAPY</span><span class="headingEndMark"> — </span>Patients who do not respond sufficiently to first-line treatment may benefit from combination therapy with an oral retinoid and psoralen plus ultraviolet A (PUVA) or from immunosuppressive therapy.</p><p class="headingAnchor" id="H257463123"><span class="h2">Re-PUVA</span><span class="headingEndMark"> — </span>The term "Re-PUVA" is often used to refer to combination therapy with an oral retinoid and oral or topical psoralen plus ultraviolet A (PUVA) photochemotherapy. The small randomized trials that have investigated the efficacy of this treatment support greater efficacy of Re-PUVA compared with either an oral retinoid or PUVA alone [<a href="#rid1">1,13,15,17</a>]. As an example, an unblinded trial in which 20 patients with bilateral palmoplantar pustulosis (PPP) were randomly assigned to treatment with oral etretinate or no etretinate and given topical PUVA only on the right hand and foot found complete clearance occurred in 6 of 10 sites treated with etretinate and PUVA, 2 of 10 sites treated with etretinate alone, 1 of 10 sites treated with PUVA alone, and none of 10 sites that received neither treatment after 12 weeks [<a href="#rid15">15</a>]. A separate 20-week randomized trial that compared etretinate and oral PUVA with oral PUVA and placebo in 17 patients with PPP and 3 patients with hyperkeratotic palmoplantar psoriasis found that combination therapy was associated with a greater likelihood of response, significantly fewer treatments required for clearance, and a shorter time to response [<a href="#rid17">17</a>]. Oral PUVA was started two weeks after the start of etretinate therapy and was given three times per week. </p><p>We usually begin <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> therapy (25 to 50 mg per day) two to four weeks before the start of PUVA therapy when administering Re-PUVA treatment. Once PUVA treatment is started, we reduce the dose of acitretin to 10 to 20 mg per day. PUVA treatments are given two or three days per week. We are cautious with the initial dose of PUVA in this population because of concern for retinoid-induced thinning of the stratum corneum resulting in an increased propensity to burn. Thus, we reduce our initial PUVA dose by 30 to 50 percent compared with the dose we would use for a patient who is not on oral retinoid therapy. (See  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy", section on 'Oral PUVA'</a>.)</p><p class="headingAnchor" id="H257463129"><span class="h2">Immunosuppressants</span><span class="headingEndMark"> — </span>Immunosuppressive therapy with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> can be beneficial for some patients with PPP. The potential for serious adverse effects should be considered prior to the initiation of these therapies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong><strong> </strong>– A few randomized trials support the use of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> for PPP. In a trial in which 40 patients with PPP were randomized to treatment with oral cyclosporine (2.5 mg/kg per day) or placebo, 17 of 19 patients who completed the four-week treatment phase had at least a 50 percent reduction in the number of pustules compared with 4 of 15 patients in the placebo group (89 versus 27 percent) [<a href="#rid18">18</a>]. Lower doses of cyclosporine may also be effective. A randomized trial by the same group in which 58 patients were randomly assigned to oral cyclosporine (1 mg/kg per day) or placebo for one month found at least a 50 percent reduction in pustules in 48 percent of 27 patients in the cyclosporine group compared with 19 percent of 31 patients in the placebo group [<a href="#rid19">19</a>]. </p><p></p><p class="bulletIndent1">Uncontrolled studies have also suggested benefit. In a prospective study in which 48 adults with PPP received oral <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (3 mg/kg per day) for eight weeks, 17 percent achieved complete remission (≥90 percent reduction in the Palmoplantar Psoriasis Area and Severity Index [PPPASI] score), 6 percent had no response, and the remaining patients had partial improvement [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">In general, we treat adults with a 3 mg/kg dose of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and begin to taper the dose after 10 days of sustained clinical improvement (at least 75 percent improvement from baseline). We taper the dose of cyclosporine by 25 to 50 mg per week.</p><p></p><p class="bulletIndent1">Short-term use of the lowest effective dose of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is preferred to minimize adverse effects such as hypertension and renal toxicity. Our typical duration of cyclosporine treatment lasts 12 to 24 weeks. Close monitoring for side effects is required. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1">Our personal experience suggests that higher doses of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> may be effective for some patients who fail to respond to 3 mg/kg per day; we have successfully used doses of up to 8 mg/kg per day. However, increased risk for side effects is a concern for treatment with higher doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methotrexate</strong><strong> </strong>– Although our personal experience suggests that <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> can be useful for PPP, data to support this assertion are limited. A retrospective study of 114 patients with PPP or palmoplantar psoriasis found that four of seven patients with PPP who were treated with 15 to 25 mg per week of methotrexate (57 percent) achieved marked improvement in their disease [<a href="#rid4">4</a>]. A separate uncontrolled study in which patients were treated with 25 mg of methotrexate for two months found complete or almost complete resolution of PPP in 8 of 25 patients (32 percent) [<a href="#rid21">21</a>]. Most of the responders also had psoriatic skin lesions at other sites. </p><p></p><p class="bulletIndent1">We typically treat adults with 7.5 to 22.5 mg of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> <strong>per week</strong> given intramuscularly or subcutaneously. Methotrexate is <strong>not</strong> given daily. Oral administration of methotrexate (10 to 25 mg per week) is an additional option, though the risk for drug-related gastrointestinal distress may be higher. </p><p></p><p class="bulletIndent1">Methods for beginning <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> therapy vary. We usually begin at a dose of 15 mg <strong>per week</strong> subcutaneously for adults. If complete blood count with differential and liver function test results are normal at weeks 2 and 4 of treatment, we continue giving 15 mg per week. We expect to see clinical improvement within 12 to 16 weeks.</p><p></p><p class="bulletIndent1">If the response to <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> is not satisfactory after 12 to 16 weeks, we increase the dose to 17.5 mg per week and re-evaluate the patient after four weeks. If no improvement is seen, we discontinue methotrexate and proceed to an alternative therapy. If improvement is seen but not satisfactory, we increase the dose to 20 mg per week for an additional four weeks and then increase up to a maximum dose of 22.5 mg per week if the response to 20 mg per week is inadequate. We discontinue methotrexate if patients have an inadequate response to 22.5 mg per week.</p><p></p><p class="bulletIndent1">Following achievement of satisfactory improvement, we aim to taper the dose to 5 to 7.5 mg per week for maintenance therapy.</p><p></p><p class="bulletIndent1">Monitoring for adverse effects is important during <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> therapy, particularly at the start of therapy and following dose increases. Hematologic toxicity is a potentially life-threatening side effect. Gastrointestinal distress and liver or pulmonary toxicity are additional side effects. Liver and renal function tests should be monitored periodically. <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">Folic acid</a> supplementation should be given to patients receiving methotrexate therapy to reduce the risk of some side effects. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a> and  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate", section on 'Prevention of side effects with folate'</a>.)</p><p></p><p class="headingAnchor" id="H257463135"><span class="h1">SEVERE RECALCITRANT DISEASE</span><span class="headingEndMark"> — </span>Despite the observation that biologic anti-tumor necrosis factor (anti-TNF) drugs (<a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, and <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>) may induce palmoplantar pustulosis (PPP) [<a href="#rid22">22,23</a>], there is some evidence that these agents can be effective for treating PPP. A 24-week, randomized trial supports the efficacy of etanercept for PPP [<a href="#rid24">24</a>]. TNF-alpha inhibitors also have been reported as effective for the treatment of SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome, a disorder that may present with PPP [<a href="#rid25">25-30</a>]. (See  <a class="medical medical_review" href="/z/d/html/89272.html" rel="external">"Palmoplantar pustulosis: Epidemiology, clinical features, and diagnosis", section on 'SAPHO syndrome'</a>.)</p><p>Treatment with other biologic agents has been attempted for severe or recalcitrant PPP occurring with or without associated plaque psoriasis. Data suggesting a role for interleukin (IL) 23 production and the resulting proliferation of T helper type 17 (Th17) cells and Th17 cytokines (eg, IL-17A, IL-17F, IL-22) in the pathogenesis of PPP has contributed to trials of therapies that inhibit this pathway [<a href="#rid31">31-33</a>] (see  <a class="medical medical_review" href="/z/d/html/89272.html" rel="external">"Palmoplantar pustulosis: Epidemiology, clinical features, and diagnosis", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/z/d/html/15277.html" rel="external">"Pathophysiology of plaque psoriasis", section on 'T helper type 17 cells'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ustekinumab</strong><strong> </strong>– The efficacy of <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, a biologic inhibitor of IL-12 and IL-23, for PPP is uncertain. A 16-week randomized trial that included 13 patients with PPP and 20 patients with palmoplantar pustular psoriasis failed to find a statistically significant difference in the response of patients to ustekinumab (45 mg given at weeks 0 and 4) versus placebo [<a href="#rid34">34</a>]. However, benefit of ustekinumab for PPP or palmoplantar pustular psoriasis has been reported in an uncontrolled study, case series, and case reports [<a href="#rid35">35-40</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guselkumab</strong><strong> </strong>– Two randomized trials suggest benefit of <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, another biologic agent targeting IL-23 [<a href="#rid41">41,42</a>]. In a phase 3 trial, 159 adults with refractory PPP were randomly assigned to guselkumab 100 mg, guselkumab 200 mg, or placebo given at weeks 0, 4, and 12 and then every 8 weeks thereafter [<a href="#rid42">42</a>]. Patients in the placebo group were rerandomized to guselkumab 100 mg or guselkumab 200 mg after week 16. At week 16, both the 100 mg and 200 mg guselkumab groups exhibited greater improvement in the Palmoplantar Psoriasis Area and Severity Index (PPPASI) total score than the placebo group (least squares mean change of -15.3, -11.7, and -7.6, respectively). In addition, more patients in the guselkumab 100 mg group had at least 50 percent improvement in the PPPASI total score (PPPASI-50) at week 16 than in the placebo group (57 versus 34 percent). Although the proportion of patients achieving this endpoint in the guselkumab 200 mg group (37 percent) was similar to the placebo group, increasing response to guselkumab was detected over time, and PPPASI-50 response rates at week 52 were similar in the 100 mg and 200 mg guselkumab groups (83 and 85 percent, respectively). Sustained efficacy and safety of guselkumab for PPP through week 84 has been demonstrated in patients with PPP [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secukinumab</strong><strong> </strong>– Additional study is necessary to clarify the effects of <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, an anti-IL-17A monoclonal antibody. In the 2PRECISE trial (n = 237), patients with moderate to severe palmoplantar pustular psoriasis were randomly assigned to 300 mg of secukinumab, 150 mg of secukinumab, or placebo given at weeks 1, 2, 3, and 4 and then every four weeks. The trial did not achieve the primary endpoint of superiority of the 300 or 150 mg doses of secukinumab over placebo after 16 weeks (27, 18, and 14 percent achieved 75 percent improvement in the PPPASI score, respectively) [<a href="#rid44">44</a>]. Although benefit of a longer course of treatment was proposed based upon a second phase in which patients in the secukinumab groups were allowed to continue treatment and nonresponders in the placebo group were rerandomized to 300 or 150 mg of secukinumab, further study to confirm benefit is warranted. At week 52, 42 percent of patients in the secukinumab 300 mg group and 35 percent of patients in the secukinumab 150 mg group achieved at least 75 percent improvement in the PPPASI score.</p><p></p><p>The efficacy of other biologic and small molecule therapies used for psoriasis is unclear. Improvement of PPP with <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a>, or <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> has been reported in individual patients [<a href="#rid45">45-47</a>]. In a series of four patients treated with <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a> (including two who failed to respond to <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>) for severe, recalcitrant PPP associated with plaque psoriasis and/or psoriatic arthritis, three did not respond to treatment and one had a partial response but discontinued therapy due to oral candidiasis [<a href="#rid48">48</a>]. </p><p><a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">Anakinra</a>, a biologic IL-1 inhibitor, did not appear effective for PPP in an eight-week, placebo-controlled, randomized trial (n = 64) [<a href="#rid49">49</a>]. However, improvement of severe or recalcitrant palmoplantar pustular psoriasis or acrodermatitis continua of Hallopeau (pustular psoriasis of the digits) during treatment with anakinra has been documented in case reports [<a href="#rid50">50,51</a>]. <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">Canakinumab</a> was not effective for palmoplantar pustular psoriasis in a case report [<a href="#rid52">52</a>]. </p><p>Examples of additional therapies under investigation for PPP include the IL-36 inhibitors <a class="drug drug_general" data-topicid="139549" href="/z/d/drug information/139549.html" rel="external">spesolimab</a> and imsidolimab [<a href="#rid53">53-55</a>], RIST4721 (a CXC chemokine receptor type 2 antagonist) [<a href="#rid56">56</a>], and CSL324 (a recombinant anti-granulocyte colony-stimulating factor receptor monoclonal antibody) [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H257463141"><span class="h1">OTHER THERAPIES</span><span class="headingEndMark"> — </span>Other interventions have been reported to be useful for palmoplantar pustulosis (PPP), including other topical and systemic drugs, tonsillectomy, a gluten-free diet in patients with associated gluten intolerance, and light-based or radiation therapy. Data on most of these therapies are limited:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other topical drugs </strong>– In addition to topical corticosteroids, which represent the mainstay of topical therapy for PPP, topical therapies such as topical retinoids, tar, <a class="drug drug_general" data-topicid="8814" href="/z/d/drug information/8814.html" rel="external">anthralin</a>, or <a class="drug drug_general" data-topicid="9181" href="/z/d/drug information/9181.html" rel="external">calcipotriol</a> are sometimes used in the clinical setting, though there are few data to support their efficacy. No randomized trials have evaluated the efficacy of these therapies. We have not had success with these therapies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral tetracyclines </strong>– Oral tetracyclines are a less commonly used treatment for PPP. Two randomized crossover trials in which patients were treated with <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> or clomocycline support the efficacy of these drugs over placebo for inducing improvement in PPP [<a href="#rid58">58,59</a>]. We do not use oral tetracyclines for PPP. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colchicine</strong><strong> </strong>– Although <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> was associated with marked improvement in 15 of 25 patients treated for PPP in a retrospective study [<a href="#rid4">4</a>], findings of randomized trials have been disappointing [<a href="#rid60">60,61</a>]. In addition, rates of adverse effects (diarrhea, headaches, and nausea) in the randomized trials were high.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Itraconazole</strong><strong> </strong>– Two small case series document clinical improvement in PPP (especially new pustule formation) during treatment with <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> [<a href="#rid62">62,63</a>]. Relapses occurred after cessation of therapy. No randomized trials have evaluated the efficacy of itraconazole therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tonsillectomy </strong>– Japanese studies linking PPP to tonsillar infections and reports of improvement in PPP following tonsillectomy suggest that some patients may benefit from this procedure [<a href="#rid64">64-66</a>]. Improvement of PPP after tonsillectomy has been reported in several Japanese series [<a href="#rid64">64,67-69</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gluten-free diet </strong>– Patients with gluten sensitivity and PPP may benefit from gluten-free diet [<a href="#rid70">70</a>]. In a Swedish series, all of nine patients who had elevated anti-gliadin antibodies and/or elevated tissue transglutaminase antibodies and adhered to a gluten-free diet experienced clearance or great improvement in PPP [<a href="#rid70">70</a>]. Improvement was slow, occurring over the course of a few months in patients with moderate PPP and over several years in patients with longstanding severe PPP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other light-based therapies </strong>– Exposure to an excimer light source or a narrowband ultraviolet B (UVB) light source has been associated with improvement in PPP in uncontrolled studies [<a href="#rid71">71-73</a>]. Findings of an eight-week, randomized trial (n = 77) that compared three dose regimens for excimer laser therapy for PPP suggest that higher-dose regimens may be of greater benefit than lower-dose regimens but are also associated with greater risk of side effects [<a href="#rid74">74</a>]. An ultraviolet A1 (UVA1) 355 nm laser appeared effective for PPP in an uncontrolled study [<a href="#rid75">75</a>]. Responses to photodynamic therapy have been documented in case reports [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy </strong>–<strong> </strong>Limited data suggest benefit of superficial radiation therapy [<a href="#rid77">77,78</a>]. A six-week trial in which 17 patients with PPP were randomly assigned to treatment of PPP on one side of the body with Grenz ray therapy and a sham treatment on the contralateral side found greater improvement in PPP on the side of the body exposed to Grenz rays [<a href="#rid77">77</a>]. However, the response was moderate, and no patients achieved disease clearance. In two case reports, superficial radiation therapy administered with a megavoltage beams technique was associated with dramatic, rapid improvement of severe, refractory PPP [<a href="#rid78">78</a>]. </p><p></p><p>Other interventions described as beneficial in case reports include oral <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> [<a href="#rid79">79</a>] and high-dose rate brachytherapy [<a href="#rid80">80</a>]. </p><p class="headingAnchor" id="H257463147"><span class="h1">PATIENT FOLLOW-UP</span><span class="headingEndMark"> — </span>The purpose of patient follow-up is to assess the response to treatment and to evaluate for adverse effects. Therefore, the frequency of follow-up should be individualized based upon the severity of disease and the selected therapeutic regimen. Patients with poorly controlled or severe disease on systemic therapy will require more frequent follow-up than patients with milder disease.</p><p class="headingAnchor" id="H812448164"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/132532.html" rel="external">"Society guideline links: Palmoplantar pustulosis"</a>.)</p><p class="headingAnchor" id="H257469555"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Palmoplantar pustulosis (PPP) is a skin disorder that presents with recurrent eruptions of pustules on the palms or soles  (<a class="graphic graphic_picture graphicRef75404 graphicRef62582 graphicRef82843 graphicRef93903 graphicRef93904 graphicRef93905" href="/z/d/graphic/75404.html" rel="external">picture 1A-F</a>). PPP is associated with symptoms of pruritus, burning sensations, or pain in involved areas and can have a significant negative effect on quality of life. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/z/d/html/89272.html" rel="external">"Palmoplantar pustulosis: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">PPP exhibits a chronic course characterized by exacerbations and partial remissions and can be difficult to treat. Treatment consists of interventions to reduce associated symptoms, smoking cessation, and various medical therapies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin moisturization and avoidance of irritants </strong>– In an attempt to reduce associated symptoms of PPP, we advise patients to keep skin moisturized and to avoid irritants that may exacerbate PPP. (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking cessation </strong>– Although data are insufficient for conclusions on the effect of smoking cessation on the course of PPP, we encourage all patients to stop smoking. There is a strong relationship between smoking and the development of PPP. (See <a class="local">'General measures'</a> above and  <a class="medical medical_review" href="/z/d/html/89272.html" rel="external">"Palmoplantar pustulosis: Epidemiology, clinical features, and diagnosis", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic therapy </strong>– Therapeutic options include topical therapy, systemic therapy, and photochemotherapy. No treatment is uniformly effective, and the response to treatment is unpredictable (see <a class="local">'Overview'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy for limited disease </strong>– For patients with PPP that is limited to focal areas of involvement, we suggest a super high-potency topical corticosteroid applied under occlusion for the initial treatment of PPP (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment for diffuse disease </strong>– For patients with diffuse eruptions on the palms and/or soles, we suggest initial treatment with oral <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> or oral psoralen plus ultraviolet A (PUVA) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Topical corticosteroid therapy may be administered concomitantly. (See <a class="local">'First-line therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Failure of initial treatment </strong>– Patients who do not respond to treatment with topical corticosteroids, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, or PUVA may benefit from other therapies. Combination therapy with acitretin and PUVA and systemic treatment with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> are our preferred second-line options for therapy. (See <a class="local">'Second-line therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Marsland AM, Chalmers RJ, Hollis S, et al. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev 2006; :CD001433.</a></li><li><a class="nounderline abstract_t">Brunasso AM, Puntoni M, Aberer W, et al. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol 2013; 168:1243.</a></li><li><a class="nounderline abstract_t">Michaëlsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol 2006; 54:737.</a></li><li><a class="nounderline abstract_t">Adişen E, Tekin O, Gülekon A, Gürer MA. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol 2009; 23:814.</a></li><li><a class="nounderline abstract_t">Sevrain M, Richard MA, Barnetche T, et al. Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. J Eur Acad Dermatol Venereol 2014; 28 Suppl 5:13.</a></li><li><a class="nounderline abstract_t">Kragballe K, Larsen FG. A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pustulosis. Acta Derm Venereol 1991; 71:540.</a></li><li><a class="nounderline abstract_t">Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988; 119:755.</a></li><li><a class="nounderline abstract_t">Irla N, Navarini AA, Yawalkar N. Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis. Br J Dermatol 2012; 167:1170.</a></li><li><a class="nounderline abstract_t">Reich K, Graff O, Mehta N. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study. Br J Dermatol 2016; 174:1277.</a></li><li><a class="nounderline abstract_t">Lassus A, Lauharanta J, Juvakoski T, Kanerva L. Efficacy of etretinate (Tigason) in clearing and prevention of relapse of palmoplantar pustulosis. Dermatologica 1983; 166:215.</a></li><li><a class="nounderline abstract_t">Aldrich MS, Foster NL, White RF, et al. Sleep abnormalities in progressive supranuclear palsy. Ann Neurol 1989; 25:577.</a></li><li><a class="nounderline abstract_t">Murray D, Corbett MF, Warin AP. A controlled trial of photochemotherapy for persistent palmoplantar pustulosis. Br J Dermatol 1980; 102:659.</a></li><li><a class="nounderline abstract_t">Rosén K, Mobacken H, Swanbeck G. PUVA, etretinate, and PUVA-etretinate therapy for pustulosis palmoplantaris. A placebo-controlled comparative trial. Arch Dermatol 1987; 123:885.</a></li><li><a class="nounderline abstract_t">Lassus A, Lauharanta J, Eskelinen A. The effect of etretinate compared with different regimens of PUVA in the treatment of persistent palmoplantar pustulosis. Br J Dermatol 1985; 112:455.</a></li><li><a class="nounderline abstract_t">Matsunami E, Takashima A, Mizuno N, et al. Topical PUVA, etretinate, and combined PUVA and etretinate for palmoplantar pustulosis: comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections. J Dermatol 1990; 17:92.</a></li><li><a class="nounderline abstract_t">Layton AM, Sheehan-Dare R, Cunliffe WJ. A double-blind, placebo-controlled trial of topical PUVA in persistent palmoplantar pustulosis. Br J Dermatol 1991; 124:581.</a></li><li><a class="nounderline abstract_t">Lawrence CM, Marks J, Parker S, Shuster S. A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis. Br J Dermatol 1984; 110:221.</a></li><li><a class="nounderline abstract_t">Reitamo S, Erkko P, Remitz A, et al. Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study. Arch Dermatol 1993; 129:1273.</a></li><li><a class="nounderline abstract_t">Erkko P, Granlund H, Remitz A, et al. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol 1998; 139:997.</a></li><li><a class="nounderline abstract_t">Jin XH, Chen X, Mou Y, Xia JX. Effects of Cyclosporine on Palmoplantar Pustulosis and Serum Expression of IL-17, IL-23, and TNF-α. Dermatol Ther (Heidelb) 2019; 9:547.</a></li><li><a class="nounderline abstract_t">Thomsen K. Pustulosis palmaris et plantaris treated with methotrexate. Acta Derm Venereol 1971; 51:397.</a></li><li><a class="nounderline abstract_t">Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: A way to treat and trigger? Acta Derm Venereol 2010; 90:183.</a></li><li><a class="nounderline abstract_t">Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 2012; 67:e179.</a></li><li><a class="nounderline abstract_t">Bissonnette R, Poulin Y, Bolduc C, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol 2008; 7:940.</a></li><li><a class="nounderline abstract_t">Hampton SL, Youssef H. Successful treatment of resistant SAPHO syndrome with anti-TNF therapy. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">De Souza A, Solomon GE, Strober BE. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull NYU Hosp Jt Dis 2011; 69:185.</a></li><li><a class="nounderline abstract_t">Arias-Santiago S, Sanchez-Cano D, Callejas-Rubio JL, et al. Adalimumab treatment for SAPHO syndrome. Acta Derm Venereol 2010; 90:301.</a></li><li><a class="nounderline abstract_t">Ben Abdelghani K, Dran DG, Gottenberg JE, et al. Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 2010; 37:1699.</a></li><li><a class="nounderline abstract_t">Fruehauf J, Cierny-Modrè B, Caelen Lel-S, et al. Response to infliximab in SAPHO syndrome. BMJ Case Rep 2009; 2009.</a></li><li><a class="nounderline abstract_t">Sabugo F, Liberman C, Niedmann JP, et al. Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism. Clin Rheumatol 2008; 27:533.</a></li><li><a class="nounderline abstract_t">Murakami M, Hagforsen E, Morhenn V, et al. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol 2011; 20:845.</a></li><li><a class="nounderline abstract_t">Hagforsen E, Hedstrand H, Nyberg F, Michaëlsson G. Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br J Dermatol 2010; 163:572.</a></li><li><a class="nounderline abstract_t">Kim DY, Kim JY, Kim TG, et al. A comparison of inflammatory mediator expression between palmoplantar pustulosis and pompholyx. J Eur Acad Dermatol Venereol 2013; 27:1559.</a></li><li><a class="nounderline abstract_t">Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol 2014; 28:1298.</a></li><li><a class="nounderline abstract_t">Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol 2010; 163:1116.</a></li><li><a class="nounderline abstract_t">Bertelsen T, Kragballe K, Johansen C, Iversen L. Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. Int J Dermatol 2014; 53:e464.</a></li><li><a class="nounderline abstract_t">Morales-Múnera C, Vilarrasa E, Puig L. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol 2013; 168:820.</a></li><li><a class="nounderline abstract_t">Chu DH, Van Voorhees AS, Rosenbach M. Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases. Arch Dermatol 2011; 147:1228.</a></li><li><a class="nounderline abstract_t">Puig L, Morales-Múnera CE, López-Ferrer A, Geli C. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 2012; 225:14.</a></li><li><a class="nounderline abstract_t">Pinto-Almeida T, Torres T, Sanches M, Selores M. Treatment of palmoplantar pustulosis with ustekinumab--the importance of interfering with the IL23/Th17 pathway. Eur J Dermatol 2013; 23:916.</a></li><li><a class="nounderline abstract_t">Terui T, Kobayashi S, Okubo Y, et al. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial. JAMA Dermatol 2018; 154:309.</a></li><li><a class="nounderline abstract_t">Terui T, Kobayashi S, Okubo Y, et al. Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol 2019; 155:1153.</a></li><li><a class="nounderline abstract_t">Okubo Y, Morishima H, Zheng R, Terui T. Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study. J Dermatol 2021; 48:1838.</a></li><li><a class="nounderline abstract_t">Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study. J Am Acad Dermatol 2019; 80:1344.</a></li><li><a class="nounderline abstract_t">Haynes D, Topham C, Hagstrom E, Greiling T. Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: A case report. Australas J Dermatol 2020; 61:e108.</a></li><li><a class="nounderline abstract_t">Haebich G, Kalavala M. Successful treatment of refractory palmoplantar pustulosis with apremilast. Clin Exp Dermatol 2017; 42:471.</a></li><li><a class="nounderline abstract_t">Del Campo DC. Successful Use of Tildrakizumab for Treatment of Palmoplantar Pustulosis: A Case Report. J Drugs Dermatol 2021; 20:1117.</a></li><li><a class="nounderline abstract_t">Pinter A, Wilsmann-Theis D, Peitsch WK, Mössner R. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases. J Dermatol 2019; 46:426.</a></li><li><a class="nounderline abstract_t">Cro S, Cornelius VR, Pink AE, et al. Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT). Br J Dermatol 2021.</a></li><li><a class="nounderline abstract_t">Tauber M, Viguier M, Alimova E, et al. Partial clinical response to anakinra in severe palmoplantar pustular psoriasis. Br J Dermatol 2014; 171:646.</a></li><li><a class="nounderline abstract_t">Lutz V, Lipsker D. Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra. Arch Dermatol 2012; 148:297.</a></li><li><a class="nounderline abstract_t">Mansouri B, Kivelevitch D, Campa M, Menter A. Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumab. Clin Exp Dermatol 2016; 41:324.</a></li><li><a class="nounderline abstract_t">Mrowietz U, Burden AD, Pinter A, et al. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb) 2021; 11:571.</a></li><li class="breakAll">A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab. https://www.clinicaltrials.gov/ct2/show/NCT04493424 (Accessed on April 04, 2022).</li><li class="breakAll">A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis (POPLAR). https://www.clinicaltrials.gov/ct2/show/NCT03633396 (Accessed on April 04, 2022).</li><li class="breakAll">A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP). https://www.clinicaltrials.gov/ct2/show/NCT03988335 (Accessed on April 04, 2022).</li><li class="breakAll">Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis. https://www.clinicaltrials.gov/ct2/show/NCT03972280 (Accessed on April 04, 2022).</li><li><a class="nounderline abstract_t">Thomsen K, Osterbye P. Pustulosis palmaris et plantaris. Br J Dermatol 1973; 89:293.</a></li><li><a class="nounderline abstract_t">Ward JM, Corbett MF, Hanna MJ. A double-blind trial of clomocycline in the treatment of persistent palmoplantar pustulosis. Br J Dermatol 1976; 95:317.</a></li><li><a class="nounderline abstract_t">Thestrup-Pedersen K, Reymann F. Treatment of pustulosis palmaris et plantaris with colchicine. A double-blind cross-over trial. Acta Derm Venereol 1984; 64:76.</a></li><li><a class="nounderline abstract_t">Mann RJ. Failure of colchicine for palmo-plantar pustulosis. Br J Dermatol 1982; 106:373.</a></li><li><a class="nounderline abstract_t">V'lckova-Laskoska MT, Caca-Biljanovska NG, Laskoski DS, Kamberova SJ. Palmoplantar pustulosis treated with itraconazole: a single, active-arm pilot study. Dermatol Ther 2009; 22:85.</a></li><li><a class="nounderline abstract_t">Mihara M, Hagari Y, Morimura T, et al. Itraconazole as a new treatment for pustulosis palmaris et plantaris. Arch Dermatol 1998; 134:639.</a></li><li><a class="nounderline abstract_t">Takahara M. Clinical outcome of tonsillectomy for palmoplantar pustulosis and etiological relationship between palmoplantar pustulosis and tonsils. Adv Otorhinolaryngol 2011; 72:86.</a></li><li><a class="nounderline abstract_t">Kikuchi N, Yamamoto T. Dental infection as a triggering factor in palmoplantar pustulosis. Acta Derm Venereol 2013; 93:721.</a></li><li><a class="nounderline abstract_t">Akiyama T, Seishima M, Watanabe H, et al. The relationships of onset and exacerbation of pustulosis palmaris et plantaris to smoking and focal infections. J Dermatol 1995; 22:930.</a></li><li><a class="nounderline abstract_t">Ono T. Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris. J Dermatol 1977; 4:163.</a></li><li><a class="nounderline abstract_t">Ono T, Jono M, Kito M, et al. Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris. Acta Otolaryngol Suppl 1983; 401:12.</a></li><li><a class="nounderline abstract_t">Noda Y, Ura M. Pustulosis palmaris et plantaris due to tonsillar focal infections. From the analysis of long-term observed cases. Acta Otolaryngol Suppl 1983; 401:22.</a></li><li><a class="nounderline abstract_t">Michaëlsson G, Kristjánsson G, Pihl Lundin I, Hagforsen E. Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. Br J Dermatol 2007; 156:659.</a></li><li><a class="nounderline abstract_t">Fumimori T, Tsuruta D, Kawakami T, et al. Effect of monochromatic excimer light on palmoplantar pustulosis: a clinical study performed in a private clinic by a dermatological specialist. J Dermatol 2013; 40:1004.</a></li><li><a class="nounderline abstract_t">Aubin F, Vigan M, Puzenat E, et al. Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses. Br J Dermatol 2005; 152:99.</a></li><li><a class="nounderline abstract_t">Kawada A, Matsuda H, Oiso N. Efficacy and safety of targeted narrowband ultraviolet B therapy using a flat-type fluorescent lamp for the treatment of palmoplantar pustulosis. J Dermatol 2013; 40:754.</a></li><li><a class="nounderline abstract_t">Peng C, Hu Y, Chen W, et al. A randomized prospective study of different dose regimens using the 308-nm excimer laser in the treatment of palmoplantar pustulosis. Dermatol Ther 2021; 34:e15079.</a></li><li><a class="nounderline abstract_t">Nisticò SP, Saraceno R, Chiricozzi A, et al. UVA-1 laser in the treatment of palmoplantar pustular psoriasis. Photomed Laser Surg 2013; 31:434.</a></li><li><a class="nounderline abstract_t">Kim JY, Kang HY, Lee ES, Kim YC. Topical 5-aminolaevulinic acid photodynamic therapy for intractable palmoplantar psoriasis. J Dermatol 2007; 34:37.</a></li><li><a class="nounderline abstract_t">Lindelöf B, Beitner H. The effect of grenz ray therapy on pustulosis palmoplantaris. A double-blind bilateral trial. Acta Derm Venereol 1990; 70:529.</a></li><li><a class="nounderline abstract_t">King BJ, Langeveld AP, Davis MDP, Martenson JA. Skin-directed radiation therapy for palmoplantar pustulosis. JAAD Case Rep 2019; 5:478.</a></li><li><a class="nounderline abstract_t">Koga T, Sato T, Umeda M, et al. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation. Clin Immunol 2016; 173:147.</a></li><li><a class="nounderline abstract_t">Timerman D, Devlin PM, Nambudiri VE, et al. Novel application of high-dose rate brachytherapy for severe, recalcitrant palmoplantar pustulosis. Clin Exp Dermatol 2016; 41:498.</a></li></ol></div><div id="topicVersionRevision">Topic 93852 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16437433" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Interventions for chronic palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23301847" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16546609" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470063" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24985558" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1685841" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2974306" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22612660" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26800106" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6343148" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy of etretinate (Tigason) in clearing and prevention of relapse of palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2742360" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sleep abnormalities in progressive supranuclear palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7000136" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A controlled trial of photochemotherapy for persistent palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3300565" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : PUVA, etretinate, and PUVA-etretinate therapy for pustulosis palmoplantaris. A placebo-controlled comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3888246" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The effect of etretinate compared with different regimens of PUVA in the treatment of persistent palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2184179" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Topical PUVA, etretinate, and combined PUVA and etretinate for palmoplantar pustulosis: comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2064943" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A double-blind, placebo-controlled trial of topical PUVA in persistent palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6696838" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8215491" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9990362" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31240637" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of Cyclosporine on Palmoplantar Pustulosis and Serum Expression of IL-17, IL-23, and TNF-α.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4109281" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pustulosis palmaris et plantaris treated with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20169304" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Paradoxical reactions to targeted biological treatments: A way to treat and trigger?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752492" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-αinhibitors: the Mayo Clinic experience, 1998 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19112757" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Etanercept in the treatment of palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23355559" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Successful treatment of resistant SAPHO syndrome with anti-TNF therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22035400" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20526553" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adalimumab treatment for SAPHO syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472920" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Tumor necrosis factor-alpha blockers in SAPHO syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21686446" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Response to infliximab in SAPHO syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17938987" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21732985" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20426778" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23802874" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A comparison of inflammatory mediator expression between palmoplantar pustulosis and pompholyx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24112799" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20545680" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ustekinumab in the treatment of palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24962808" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23210683" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22006150" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22890275" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24280259" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of palmoplantar pustulosis with ustekinumab--the importance of interfering with the IL23/Th17 pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29417135" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31268476" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34453358" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30716404" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31318041" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28239890" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Successful treatment of refractory palmoplantar pustulosis with apremilast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34636515" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Successful Use of Tildrakizumab for Treatment of Palmoplantar Pustulosis: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30786053" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34411292" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24684162" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Partial clinical response to anakinra in severe palmoplantar pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431771" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26344848" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Palmoplantar pustular psoriasis unresponsive to the interleukin-1βantagonist canakinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33661508" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33661508" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33661508" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33661508" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33661508" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4582718" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pustulosis palmaris et plantaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/788767" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A double-blind trial of clomocycline in the treatment of persistent palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6203289" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of pustulosis palmaris et plantaris with colchicine. A double-blind cross-over trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7039659" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Failure of colchicine for palmo-plantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19222520" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Palmoplantar pustulosis treated with itraconazole: a single, active-arm pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9606344" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Itraconazole as a new treatment for pustulosis palmaris et plantaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21865698" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical outcome of tonsillectomy for palmoplantar pustulosis and etiological relationship between palmoplantar pustulosis and tonsils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23462950" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Dental infection as a triggering factor in palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8648000" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The relationships of onset and exacerbation of pustulosis palmaris et plantaris to smoking and focal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15461345" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6582755" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6582756" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pustulosis palmaris et plantaris due to tonsillar focal infections. From the analysis of long-term observed cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17263812" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24303875" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effect of monochromatic excimer light on palmoplantar pustulosis: a clinical study performed in a private clinic by a dermatological specialist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15656808" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855773" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Efficacy and safety of targeted narrowband ultraviolet B therapy using a flat-type fluorescent lamp for the treatment of palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34333826" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A randomized prospective study of different dose regimens using the 308-nm excimer laser in the treatment of palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24047220" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : UVA-1 laser in the treatment of palmoplantar pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17204099" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Topical 5-aminolaevulinic acid photodynamic therapy for intractable palmoplantar psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1981434" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The effect of grenz ray therapy on pustulosis palmoplantaris. A double-blind bilateral trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31193518" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Skin-directed radiation therapy for palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27720846" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26848819" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Novel application of high-dose rate brachytherapy for severe, recalcitrant palmoplantar pustulosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
